Navigation Links
Amylin Pharmaceuticals to Webcast First Quarter Results
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2008 on Monday, April 21, 2008 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2008.

The call will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (888) 536-6007 (U.S./Canada) or (706) 758-4632 (international), Conference ID# 43245695. A replay of the call will also be available by phone for 24 hours beginning approximately one hour after the close of the call and can be accessed at (800) 642-1687 (U.S./Canada) or (706) 645-9291 (international), Conference ID# 43245695.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Di
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire/ - Cytochroma today announced the appointme...Dr. Moldt will replace Mr. Ulrik Spork as the Novo...mber of Board members remains unchanged at six mem...Moldt to the board and look forward to benefiting ...tinues to make progress in becoming a leading CKD-...
(Date:11/25/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Brazil Bioethanol Market Analysis and....com/p0165503/Brazil-Bioethanol-Market-Analysis-an...Market Analysis and Forecasts to 2013 ,, Summa...d forecasts of the global bioethanol market and th...
(Date:11/24/2009)...n . , Whether it,s CD packaging, containers ...y Identification) are increasingly finding their w...bel objects or goods and identify them automatical... read and process the data contained in the label....tion conditions of up to 100 degrees Celsius. But ...
(Date:11/24/2009)...o also Visit Detroit , (V...French Ambassador for International Investment, an... , , , ,What: Ambassador Appia is available to me...atives adopted by France to further develop the fi...ion and development., , ,When: Available for Inter...
Breaking Biology Technology:Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10Intelligence inside metal components 2
... Amarin Corporation plc,(NASDAQ: AMRN ) today an...th,Scarista Limited ("Scarista") for the developme...ctual property portfolio in the field of lipid,sci...lementary to Amarin,s,existing lipid-based develop...pid transport technology. The transaction consider...
...l lead offers flexibility for placement in small, ...s, NATICK, Mass., March 3 Boston Scientific,Corp...oval of its ACUITY(R),Spiral left ventricular lead...fibrillators and cardiac resynchronization therapy...e product features a spiral design and small,lead ...
...gland and PHILADELPHIA, Pennysylvania, March 3, Sh...ecialty biopharmaceutical company, notes that Reno...ounced the results of Renovo,s latest Phase 2,stud...scar revision surgery,(RN1001-319-1009) and in bre...ss release can be found on http://www.renovo.com ...
Other Biology Technology:Amarin Secures Global Intellectual Property Rights for Lipid Programs 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 4Boston Scientific Announces European Approval of New Heart Failure Lead 2Boston Scientific Announces European Approval of New Heart Failure Lead 3Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 2Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3
(Date:11/26/2009)...hat are the bare essentials of life, the indispens...an survive on its own? Can we describe the molecul... organism functions as a system? These are just so...ip between the European Molecular Biology Laborato...e Regulacio Genmica (CRG) in Barcelona, Spain, set...
(Date:11/25/2009)...sy lives. In addition to mammalian immune systems ...alled bacteriophages, viruses that kill half the b...ria and another class of microorganisms called arc...h as deep-sea volcanic vents) manage just fine, th...nse system that helps protect them from many virus...
(Date:11/25/2009)...heart pumps some 250 million liters of blood throu...ibers of the heart have to be extremely durable. T..., vice chair of the Department of Medicine III at .... H. A. Katus), has discovered a protein that is r...lar unit, the sarcomere. In cooperation with other...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 2Specialty Technical Consultants becomes Women Owned Business Enterprise 28WBE 29 13114 1Specialty Technical Consultants becomes Women Owned Business Enterprise 28WBE 29 13114 2Specialty Technical Consultants becomes Women Owned Business Enterprise 28WBE 29 13114 3OB10 and Memorial Hermann Show How e Invoicing Program Optimized Accounts Payables and P Card Spend 52187 1OB10 and Memorial Hermann Show How e Invoicing Program Optimized Accounts Payables and P Card Spend 52187 2OB10 and Memorial Hermann Show How e Invoicing Program Optimized Accounts Payables and P Card Spend 52187 3OB10 and Memorial Hermann Show How e Invoicing Program Optimized Accounts Payables and P Card Spend 52187 4WIN Global Poll Finds Concern Of Swine Flu Decreasing Despite Not Being Prepared For A Pandemic 52183 1WIN Global Poll Finds Concern Of Swine Flu Decreasing Despite Not Being Prepared For A Pandemic 52183 2
...has to be the niche. As air and water preceded lif...shelters adult stem cells in many tissues and prov...l, must have emerged before its stem cell dependen... for Biological Studies led by Leanne Jones, Ph.D....s, now suggests that this is not always the case. ...
...ts from across the U.S. and other countries includ...versity Medical Center will discuss the latest fin... at the 11th International Fragile X Conference, t...children who are diagnosed with Fragile X also wil...romosome-linked condition, is the most common inhe...
...ch help both scientists and regulators to manage u...rch funded by the Economic and Social Research Cou...erent labs is, however, a balancing act where the ...erial need to be weighed against the need for comp...scale up the production of human embryonic stem ce...
Other Biology News:Stem cell chicken and egg debate moves to unlikely arena: the testes 2Stem cell chicken and egg debate moves to unlikely arena: the testes 3Researcher helping to pioneer medical therapy for Fragile X Syndrome presents latest findings 2Standards in stem cell research 2Standards in stem cell research 3
Mouse Anti-Rat Kappa, Lambda Light Chain Monoclonal Antibody, Horseradish Peroxidase Conjugated from AbD Serotec
Bovine Serum Albumin Peroxidase Stabilizer Solution from BioFX Laboratories, Inc.
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Axl, phospho ELISA development Kit, DuoSet, IC (Intracellular) from R&D Systems
Biology Products: